drugset

drugset / Trial / NCT07029555

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

NCT07029555 ↗

Phase 1 Active not recruiting 57 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).

Timeline

Start: 2025-06-12
Primary completion: 2028-05-15
Completion: 2028-05-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PIT565	Unknown	—	Subcutaneous

Indications